SINOMED(SH:688108) Zheng Quan Shi Bao Wang·2025-05-19 09:31Group 1 - The 2025 Oriental Cerebrovascular Disease Conference showcased clinical trial data for the self-expanding intracranial drug-eluting stent by Sino Medical, highlighting its low restenosis rates [2][4] - The 1-year restenosis rate for the Sino Medical stent was reported at only 1.87%, significantly lower than the average restenosis rate of 14.8% for existing intracranial stents [2] - Intracranial artery stenosis is a major cause of stroke in Asian populations, with a high prevalence compared to Western countries, indicating a substantial unmet medical need [2] Group 2 - The new coated flow-diverting stent demonstrated a 1-year aneurysm occlusion rate of 96.99%, the highest among similar products [3] - The stent achieved a 6-month occlusion rate of 89.78%, outperforming competitors that require a full year to reach similar results [3] - The safety composite endpoint for the new stent was reported at 1.4%, the lowest among comparable products, indicating a significant advancement in safety [3] Group 3 - The aging population is driving a rapid increase in the demand for cardiovascular disease treatments, with domestic innovations in neurointerventional devices opening new avenues for safety and efficacy [4] - Sino Medical's intracranial self-expanding drug-eluting stent system has received approval from the National Medical Products Administration and is undergoing registration in Europe and domestically [4] - The new coated flow-diverting stent is also in the registration approval process, reflecting ongoing advancements in the field [4]